Intercept Pharmaceuticals

We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, utilizing our proprietary bile acid chemistry. Our product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions. Offices in New York, San Diego and London.
Type
Public
HQ
New York, US
Founded
2002
Employees
405 (est)
Intercept Pharmaceuticals was founded in 2002 and is headquartered in New York, US

Key People at Intercept Pharmaceuticals

Mark Pruzanski

Mark Pruzanski

Founder ,CEO & Board Member
Barbara Duncan

Barbara Duncan

CFO
James Mervis

James Mervis

Chairman
Luciano Adorini

Luciano Adorini

Chief Scientific Officer
Daniel Regan

Daniel Regan

Chief Commercial Officer

Intercept Pharmaceuticals Locations

New York, US

Intercept Pharmaceuticals Metrics

Intercept Pharmaceuticals Summary

Market capitalization

$2.72 B

Closing share price

$106
Intercept Pharmaceuticals's current market capitalization is $2.72 B.

Intercept Pharmaceuticals Market Value History

Intercept Pharmaceuticals Online Presence

Intercept Pharmaceuticals News

Intercept Pharmaceuticals Company Life

You may also be interested in